The stock is trading at $6.89 impressively higher than $6.15, the 50 day moving average and which is well above the 200 day moving average of $6.15. The 50 day moving average was up by +12.06% and the 200 day average went up $0.74 or +12.07%. 344K shares changed hands on Tuesday. Volume was down 48.65% under the stocks average daily volume.
Investors are more bullish on shares of ViewRay, Inc. lately as implied by the decrease in short interest. The company realized a fall in short interest of -0.12% as of the latest report on October 13, 2017. Short interest decreased 7,274 over that period. The short-interest ratio decreased to 14.0 and the percentage of shorted shares is 0.10% as of October 13.
The following firms have recently changed their position in VRAY. Acuta Capital Partners, LLC bolstered its holdings by buying 85,314 shares an increase of 14.2%. Acuta Capital Partners, LLC now holds 686,387 shares valued at $4,441,000. The value of the position overall is down by 4.2%. Ubs Group Ag grew its position by buying 1,071 shares an increase of 525.0% as of 06/30/2017. Ubs Group Ag now controls 1,275 shares worth $8,000. The total value of its holdings increased 300.0%.
Vantage Investment Advisors, LLC expanded its investment by buying 4,000 shares an increase of 133.3% from 03/31/2017 to 06/30/2017. Vantage Investment Advisors, LLC owns 7,000 shares with a value of $45,000. The total value of its holdings increased 73.1%. Quantitative Systematic Strategies LLC augmented its stake by buying 2,967 shares an increase of 28.1% in the quarter. Quantitative Systematic Strategies LLC controls 13,531 shares with a value of $78,000. The total value of its holdings increased 16.4%.
Mizuho issued its first research report on the stock setting a rating of “Buy”.
As of the last earnings report the EPS was $-1.27 and is estimated to be $-0.82 for the current year with 59,007,000 shares presently outstanding. Next quarter’s EPS is estimated at $-0.05 with next year’s EPS projected to be $-0.29.
ViewRay, Inc., launched on October 6, 2013, through its subsidiary ViewRay Technologies, Inc., designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Business’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered..